Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women

References

• Heaney RP. Osteoporosis 2044. Osteoporosis Int 1994;4:233-7
   PubMed Web of Science ®Google Scholar
• Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997;87:1630-6
   PubMed Web of Science ®Google Scholar
• Dreinhöfer KE, Féron JM, Herrera A, et al. Orthopaedic surgeons and fragility fractures. A survey by the Bone and Joint Decade and the International Osteoporosis foundation. J Bone Joint Surg 2004;86:958-61
   PubMedGoogle Scholar
• Lippuner K, von Overbeck J, Perrelet R, et al. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporosis Int 1997;7:414-25
   PubMed Web of Science ®Google Scholar
• Chapurlat RD, Bauer DC, Nevitt M, et al. Incidence and risk factors for a second hip fracture in elderly women. The study of osteoporotic fractures. Osteoporosis Int 2003;14:130-6
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporosis Int 2004;15:38-42
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Adachi JD, Ioannidis G, Olszynski WP, et al. The impact of incident vertebral and nonvertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskel Dis 2002;3:11
   PubMed Web of Science ®Google Scholar
• Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporosis Int 1999;9:508-15
   PubMed Web of Science ®Google Scholar
• Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996;18:185S-9
   Web of Science ®Google Scholar
• Melton JL, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23
   PubMed Web of Science ®Google Scholar
• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:12-7
   PubMed Web of Science ®Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8
   PubMed Web of Science ®Google Scholar
• Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocr Metab 1996;81:3366-71
   PubMed Web of Science ®Google Scholar
• Parfitt AM, Villanueva AR, Foldes J, et al. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995;10:466-73
   PubMed Web of Science ®Google Scholar
• Baldock PA, Eisman JA. Genetic determinants of bone mass. Curr Opin Rheumatol 2004;16:450-6
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Ralston SH, Bennett ST, et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004;292:2105-14
   PubMed Web of Science ®Google Scholar
• Liu YZ, Liu YJ, Recker R, et al. Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003;177:147-96
   PubMed Web of Science ®Google Scholar
• Lips P. Which circulating level of 25 hydroxy vitamin D is appropriate? J Steroid Biochem Mol Biol 2004;89:611-4
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25
   PubMed Web of Science ®Google Scholar
• Boonen S, Bischoff-Ferrari HA, Cooper C, et al. Addressing the musculoskeletal. components of fracture risk with calcium and vitamin D: A review of the evidence. Calcified Tissue Int 2006;78:257-70
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006
   PubMed Web of Science ®Google Scholar
• Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic interventions. Endocr Rev 2001;22:477-501
   PubMed Web of Science ®Google Scholar
• Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000;82:1063-70
   PubMedGoogle Scholar
• Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-22
   PubMed Web of Science ®Google Scholar
• Port L, Center J, Briffa NK, et al. Osteoporotic fracture: missed opportunity for intervention. Osteoporosis Int 2003;14:780-4
   PubMed Web of Science ®Google Scholar
• Gehlbach SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health 2002;92:271-3
   PubMed Web of Science ®Google Scholar
• Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003;14:2-12
   PubMed Web of Science ®Google Scholar
• Panneman MJ, Lips P, Sen SS, et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporosis Int 2004;15:1201-24
   Google Scholar
• Matsumoto T, Shiraki M, Hagino H, et al. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporosis Int 2006;17:1532-8
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991;14:67-83
   PubMedGoogle Scholar
• Reeve J TJ, Parsons JA. Preliminary trial of low doses of parathyroid hormone 1-34 peptide in treatment of osteoporosis. Clin Endocrinol (Oxf) 1976;21:469-77
   Google Scholar
• Stewart AF. PTHrP (1-36) as a skeletal. anabolic agent for the treatment of osteoporosis. Bone 1996;19:303-6
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 2004;5:1153-62
   PubMed Web of Science ®Google Scholar
• Quattrochi E, Kourlas H. Teriparatide: a review. Clin Ther 2004;26:841-54
   PubMed Web of Science ®Google Scholar
• Tashjian AH Jr, Gagel RF. Teriparatide: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21:354-65
   PubMed Web of Science ®Google Scholar
• Brewer HB, Ronan R. Bovine parathyroid hormone: amino acid sequence. Proc Natl Acad Sci USA 1970;67 :1862-9
   PubMed Web of Science ®Google Scholar
• Niall HD, Keutmann H, Sauer R, et al. The amino acid sequence of bovine parathyroid hormone I. Hoppe-Seylers Zeitschrift fur Physiologische Chemie 1970;351:1586-8
   PubMedGoogle Scholar
• Nguyen-Yamamoto L, Rousseau L, Brossard J-H, et al. Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 2002;147:123-31
   PubMed Web of Science ®Google Scholar
• Jüppner H, Abou-Samra AB, Freeman M, et al. A G protein linked receptor for parathyroid hormone and parathyroid hormone related peptide. Science 1991;254:1024-6
   PubMed Web of Science ®Google Scholar
• Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992;89:2732-6.
   Google Scholar
• Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 1925;63:395-438
   Google Scholar
• Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547
   Google Scholar
• Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocrine Rev 2005;26:78-113
   PubMed Web of Science ®Google Scholar
• Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005;187 :311-25
   PubMed Web of Science ®Google Scholar
• Rixon RH, Whitfield JF, Youdale R. Increased survival of rats irradiated with x-rays and treated with parathyroid extract. Nature 1958;182:1374
   PubMed Web of Science ®Google Scholar
• Rixon RH, Whitfield JF. Parathyroid hormone: a possible initiator of liver regeneration. Proc Soc Exp Biol Med 1972;141:93-7
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Perris AD, Youdale T. The calcium-mediated promotion of mitotic activity in rat thymocyte populations by growth hormone, neurohormones, parathyroid hormone and prolactin. J Cell Physiol 1969;73:203-11
   PubMed Web of Science ®Google Scholar
• Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5
   PubMed Web of Science ®Google Scholar
• Garabedian M, Holick MF, Deluca HF, et al. Control of 25-hydroxycalciferol metabolism by parathyroid glands. Proc Natl Acad Sci USA 1972;69:1673-6
   PubMed Web of Science ®Google Scholar
• Fraser DR, Kodicek E. Regulation of 25 hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nature New Biology 1973;241:163-6
   PubMedGoogle Scholar
• Nemere I, Larsson D. Does PTH have a direct effect on the intestine? J Cell Biochem 2002;86:29-34
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Jüppner HW, Gardella TJ, Brown EM. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development, 4th edn. Philadelphia: Elsevier, 2000.
   Google Scholar
• Bilezikian JP, Brandi ML, Rubin M, et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257:6-17
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
   Google Scholar
• Borah B, Dufresne TE, Ritman EL, et al. Long term risedronate treatment normalises mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-52
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment. The ICARO study. J Bone Miner Res 2006;21:1565-70
   PubMed Web of Science ®Google Scholar
• Potts JT, Tregear GW, Keutmann HT, et al. Synthesis of a biologically active N terminal tetratriacontapeptide of parathyroid hormone. Proc Natl Acad Sci USA 1971;68:63-7
   PubMed Web of Science ®Google Scholar
• Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone (1-31) NH2 and hPTH (1-34) in healthy humans. J Clin Endocrinol Metab 1999;84:2739-43
   PubMed Web of Science ®Google Scholar
• Whitfield JF. Osteoporosis-treating parathyroid hormone peptides: what are they? What do they do? How might they do it? Curr Opin Investig Drugs 2006;7:349-59
   PubMed Web of Science ®Google Scholar
• Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007;40:S5-8
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocr Metab 2005;90:2816-222
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Blake GM, Fogelman I. Long term effect of strontium ranelate treatment on BMD. J Bone Miner Res 2005;20:1901-4
   PubMed Web of Science ®Google Scholar
• Dobnig H TR. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-12
   PubMed Web of Science ®Google Scholar
• Nijweide PJ, Burger EH, Feyen JHM. Cells of the bone: proliferation, differentiation and hormonal regulation. Physiol Rev 1986;66:855-86
   PubMed Web of Science ®Google Scholar
• Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodeling. Nature 1965;206:489-90
   PubMed Web of Science ®Google Scholar
• Adami S, Kanis JA. Assessment of involutional bone loss: methodological and conceptual problems. J Bone Miner Res 1995;10:511-7
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in regulation of bone density. Cell 1997;89:309-19
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76
   PubMed Web of Science ®Google Scholar
• Hsu H, Lacey DL, Dunstan C, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-5
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Yan X-Q, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71
   PubMed Web of Science ®Google Scholar
• Li J, Morony S, Tan H, et al. Combination of TNF-α and IL-1β induced osteoclast formation and bone formation is dependent on RANK signal transduction. J Bone Miner Res 2001;16 (Supp 1):S379
   Google Scholar
• Stilgren LS, Rettmer E, Eriksen EF, et al. Skeletal. changes in osteoprotegerin and receptor activator of nuclear factor κB ligand mRNA levels in primary hyperparathyroidism: effects of parathyroidectomy and association with bone metabolism. Bone 2004;35:256-65
   Google Scholar
• Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kB ligand, osteoprotegerin and interleukin-6 levels in patients treated with glucocorticoid induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocr Metab 2004;89:3332-6
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW. Parathyroid hormone treatment can reverse corticosteroid induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709
   PubMed Web of Science ®Google Scholar
• Fox J. Developments in parathyroid hormone and related peptides as bone formation agents. Curr Opin Pharmacol 2002;2:338-44
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Søgaard CH, Danielsen CC, et al. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 1991;129:421-8
   PubMed Web of Science ®Google Scholar
• Kimmel DB, Bozzato RP, Kronis KA, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993;132:1577-84
   PubMed Web of Science ®Google Scholar
• Fox J, Miller MA, Newman MK, et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 2006;79:262-72
   PubMed Web of Science ®Google Scholar
• Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal. sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 1995;10:949-55
   Google Scholar
• Dempster DW, Moreau IA, Varela A, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months improves trabecular bone architecture: a study of iliac crest biopsies using micro-computed tomography. J Bone Miner Res 2005;20 (Supp 1):S98
   Google Scholar
• Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocr Metab 2003;88:5212-20
   PubMed Web of Science ®Google Scholar
• Roux C, Illera-Martín O, Clausen J. Efficacy of PTH (1-84) on vertebral and non-vertebral fractures in postmenopausal women with a high risk of vertebral fractures. Calcified Tissue Int 2007;80 (Supp 1):S48
   Google Scholar
• Bogado CE, Zanchetta JR, Gordon CL, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone (1-84) for 18 months decreases BMD but does not affect indices of bone strength at the distal radius. J Bone Miner Res 2006;21 (Supp 1):S112
   Google Scholar
• Hosking D, Diaz-Curiel M, Rizzoli R, et al. Serum calcium values in postmenopausal women with primary osteoporosis after treatment with full-length parathyroid hormone PTH (1-84). First results from the PEAK study. Calcified Tissue Int 2007;80:S130-1
   Google Scholar
• Diaz-Curiel M, Hosking D, Rizzoli R et al. Serum calcium values in postmenopausal women with primary osteoporosis after one month of treatment with PTH(1-84). Abstract no Su-P426 35th European Symposium on Calcified Tissues, Barcelona, Spain, 2008.
   Google Scholar
• Greenspan SL, Hanley DA, Morris SA. Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1-84 (PTH). Abstract no F389 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, USA, 2006.
   Google Scholar
• Roux C, Clausen J. Sustained effect of PTH (1-84) on the risk of vertebral fractures 12 months after cessation of therapy. Calcified Tissue Int 2007;80 (Supp 1):S146
   Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocr Metab 2000;85:2129-34
   PubMed Web of Science ®Google Scholar
• Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporosis Int 2004;15:992-7
   PubMed Web of Science ®Google Scholar
• Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5
   PubMed Web of Science ®Google Scholar
• Samnegard E, Akhter MP, Recker RR. Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats. Bone 2001;28:414-22
   PubMed Web of Science ®Google Scholar
• Fogelman I, Christiansen C, Spector T. Safety and efficacy of PTH (1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study. J Bone Miner Res 2005;20 (Supp 1):S21-2
   Google Scholar
• Fogelman I, Fordham JN, Fraser WD, et al. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcified Tissue Int 2008;83:85-92
   PubMed Web of Science ®Google Scholar
• Fox J, Miller MA, Newman MK, et al. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 2007;41 :321-30
   PubMed Web of Science ®Google Scholar
• Zanchetta JR, Bogado CE, Ferretti JL, et al. Effect of teriparatide [recombinant human parathyroid hormone (1-34] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43
   PubMed Web of Science ®Google Scholar
• Dempster DW, Zhou H, Cosman F, et al. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res 2001;16:S179
   Google Scholar
• Compston JE. Skeletal. actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007;40:1447-52
   Google Scholar
• Cosman F, Nieves JW, Zion M, et al. Daily versus cyclic parathyroid hormone in women receiving alendronate. New Engl J Med 2005;353:566-75
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocr Metab 1997;82:620-8
   PubMed Web of Science ®Google Scholar
• NICE Technology Appraisal Guidance. 2005;87
   Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration and treatment. Toxicol Pathol 2004;32:426-38
   PubMed Web of Science ®Google Scholar
• Wilker CE, Jolete J, Smith SY, et al. A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1-84) for 2 years: Role of the C terminal receptor. J Bone Miner Res 2004;19:S1-98
   Google Scholar
• Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-4
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherents to osteoporosis treatment in clinical practice. Osteoporosis Int 2006;17:914-21
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645-52
   PubMed Web of Science ®Google Scholar
• Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporosis Int 2006;17:1626-9
   PubMed Web of Science ®Google Scholar
• Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-17
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporosis Int 2006;17:201-11
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jorgensen NR, Mosekilde L, et al. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk. A meta analysis. Osteoporosis Int 2007;18:45-7
   PubMed Web of Science ®Google Scholar